Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input, 19071-19073 [2017-08354]
Download as PDF
<![CDATA[
19071
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Type of information collection
Number of
responses per
respondent
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Mail/email 1 ...........................................................................
Telephone ............................................................................
Web-based ...........................................................................
Focus Groups ......................................................................
In-person ..............................................................................
Automated 2 ..........................................................................
Cognitive Testing .................................................................
1,670
1,670
1,666
1,666
1,666
1,666
5,000
1
1
1
1
1
1
1
1,670
1,670
1,666
1,666
1,666
1,666
5,000
0.26
0.26
0.25
1.0
1.0
1.0
1.41
434.2
434.2
416.5
1,666
1,666
1,666
7,050
Total ..............................................................................
15,004
........................
15,004
........................
13,333
1 May
include telephone non-response follow-up, in which case the burden will not change.
2 May include testing of database software, CAPI software, or other automated technologies.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2017–08296 Filed 4–24–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSK3SPTVN1PROD with NOTICES
National Institute of Dental &
Craniofacial Research; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Dental and
Craniofacial Research Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Agenda: Report to the Director, NIDCR.
Place: National Institutes of Health,
Building 31C, Conference Room 10, 31
Center Drive, Bethesda, MD 20892.
Closed: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31C, Conference Room 10, 31
Center Drive, Bethesda, MD 20892.
Contact Person: Alicia J. Dombroski, Ph.D.,
Director, Division of Extramural Activities,
Natl Inst of Dental and Craniofacial Research,
National Institutes of Health, Bethesda, MD
20892, 301–594–4805, adombroski@
nidcr.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: April 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–08294 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
Name of Committee: National Advisory
Dental and Craniofacial Research Council.
Date: May 23, 2017.
Open: 8:30 a.m. to 12:30 p.m.
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee
on the Validation of Alternative
Methods; Notice of Public Meeting;
Request for Public Input
The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM) will
hold a public forum to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders. Interested persons
may attend in person or view the
meeting remotely by webcast. Time will
be set aside for questions and public
statements on the topics discussed.
Registration is requested for both public
attendance and oral statements, and
required for remote access. Information
about the meeting and registration are
available at https://ntp.niehs.nih.gov/go/
iccvamforum-2017.
DATES:
Meeting: May 23, 2017, 9:00 a.m. to
approximately 4:00 p.m. Eastern
Daylight Time (EDT).
Registration for Onsite Meeting:
Deadline is May 12, 2017.
Registration for Webcast: Deadline is
May 23, 2017.
Submission of Oral Public Statements:
Deadline is May 12, 2017.
ADDRESSES:
Meeting Location: William H. Natcher
Conference Center, National Institutes of
Health, Bethesda, MD 20892.
Meeting Web page: The preliminary
agenda, registration, and other meeting
materials are at https://ntp.niehs.nih.gov/
go/iccvamforum-2017.
FOR FURTHER INFORMATION CONTACT: Dr.
Warren Casey, Director, National
SUMMARY:
E:\FR\FM\25APN1.SGM
25APN1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
19072
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
Toxicology Program Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM);
email: warren.casey@nih.gov; telephone:
(919) 316–4729.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a
congressionally mandated committee,
promotes the development and
validation of alternative testing
strategies that protect human health and
the environment while replacing,
reducing, or refining animal use.
ICCVAM’s goals include promotion of
national and international partnerships
between governmental and
nongovernmental groups, including
academia, industry, advocacy groups,
and other key stakeholders. To foster
these partnerships ICCVAM initiated
annual public forums in 2014 to share
information and facilitate direct
communication of ideas and suggestions
from stakeholders (79 FR 25136).
This year’s meeting will be held on
May 23, 2017, at the National Institutes
of Health (NIH) in Bethesda, MD. The
meeting will include presentations by
NICEATM and ICCVAM members on
current activities related to the
development and validation of
alternative test methods and
approaches, including discussions of
the proposed strategic roadmap to
establish new approaches for evaluating
the safety of chemicals and medical
products in the United States. These
new approaches are anticipated to
increase confidence in alternative
methods and improve their relevance to
human health outcomes while
maximizing efficiency and maintaining
a commitment to replace, reduce, and
refine animal use.
Following each presentation, there
will be an opportunity for participants
to ask questions of the ICCVAM
members. Instructions for submitting
questions will be provided to remote
participants prior to the webcast. The
agenda will also include time for
participants to make public oral
statements relevant to the ICCVAM
mission and current activities.
Preliminary Agenda and Other
Meeting Information: The preliminary
agenda, list of discussion topics,
background materials, ICCVAM roster,
and public statements submitted prior
to the meeting will be posted by May 16
at https://ntp.niehs.nih.gov/go/
iccvamforum-2017. Interested
individuals are encouraged to visit this
Web page to stay abreast of the most
current meeting information.
Meeting and Registration: This
meeting is open to the public with time
scheduled for questions and oral public
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
statements following presentations from
ICCVAM and NICEATM. The public
may attend the meeting at NIH, where
attendance is limited only by the space
available, or view remotely by webcast.
Those planning to attend the meeting in
person are encouraged to register at
https://ntp.niehs.nih.gov/go/
iccvamforum-2017 by May 12, 2017, to
facilitate planning for appropriate
meeting space. Those planning to view
the webcast must register at https://
ntp.niehs.nih.gov/go/iccvamforum2017; registration will be available
through May 23, 2017. The URL for the
webcast will be provided in the email
confirming registration.
Visitor and security information for
visitors to NIH is available at https://
www.nih.gov/about/visitor/index.htm.
Individuals with disabilities who need
accommodation to participate in this
event should contact Dr. Elizabeth
Maull at phone: (919) 316–4668 or
email: maull@niehs.nih.gov. TTY users
should contact the Federal TTY Relay
Service at 800–877–8339. Requests
should be made at least five business
days in advance of the event.
Request for Oral Public Statements:
Each presentation will be followed by
an opportunity for participants to ask
questions of the presenter. Attendees
need not register in advance for the
opportunity to ask questions or make
comments specific to presentations.
Instructions for submitting questions or
comments will be provided to remote
participants prior to the webcast.
In addition to time for questions or
comments following each scheduled
presentation, time will be allotted
during the meeting for oral public
statements with associated slides on
topics relevant to ICCVAM’s mission
and topics under discussion including
the U.S. strategic roadmap. The number
and length of presentations may be
limited based on available time.
Submitters will be identified by their
name and affiliation and/or sponsoring
organization, if applicable. Persons
submitting public statements and/or
associated slides should include their
name, affiliation (if any), mailing
address, telephone, email, and
sponsoring organization (if any) with
the document. National Toxicology
Program guidelines for public
statements are at https://
ntp.niehs.nih.gov/ntp/about_ntp/
guidelines_public_comments_508.pdf.
Persons wishing to present oral public
statements are encouraged to indicate
on the registration form whether their
comments will focus on ICCVAM
agency activities or the U.S. strategic
roadmap. They should also email their
statement to ICCVAMquestions@
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
niehs.nih.gov by May 12, 2017, to allow
time for review by NICEATM and
ICCVAM and posting to the meeting
page prior to the forum. Written
statements may supplement and expand
the oral presentation. Public statements
will be distributed to NICEATM and
ICCVAM members before the meeting.
Registration for oral public statements
will be available onsite, although onsite
registration and time allotted for these
statements may be limited based on the
number of individuals who register to
make statements and available time. If
registering onsite and reading from
written text, please bring 20 copies of
the statement for distribution and to
supplement the record.
Persons wishing to present oral public
statements are strongly encouraged to
present their comments in person to
facilitate effective interaction with
ICCVAM members. However, there will
also be the opportunity to present
public statements by teleconference
line. Persons who are unable to attend
the meeting in person and wish to
present oral public statements should
email ICCVAMquestions@niehs.nih.gov
by May 12, 2017 to arrange to present
statements via teleconference line.
Responses to this notice are
voluntary. No proprietary, classified,
confidential, or sensitive information
should be included in statements
submitted in response to this notice or
presented during the meeting. This
request for input is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
submitted or for its use of that
information.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 16 federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of the NIEHS and provides
E:\FR\FM\25APN1.SGM
25APN1
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
the authority for ICCVAM involvement
in activities relevant to the development
of alternative test methods. ICCVAM
acts to ensure that new and revised test
methods are validated to meet the needs
of federal agencies, increase the
efficiency and effectiveness of federal
agency test method review, and
optimize utilization of scientific
expertise outside the federal
Government. Additional information
about ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative testing
approaches for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: April 13, 2017.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2017–08354 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
asabaliauskas on DSK3SPTVN1PROD with NOTICES
National Cancer Institute; Cancellation
of Meeting
Notice is hereby given of the
cancellation of the National Cancer
Institute Special Emphasis Panel, May
1, 2017, 8:00 a.m. to May 2, 2017, 1:00
p.m., Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814 which
was published in the Federal Register
on March 22, 2017, 82 FR 54.
This meeting is being amended to
cancel the meeting on May 1–2, 2017.
Dated: April 20, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Chris Kornak, 240–627–3705,
chris.kornak@nih.gov. Licensing
information and copies of the U.S.
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
A Second CD4-Binding Region of
HIV–1 gp120 Critical for Viral
Infectivity: New Methods for Treatment
and Vaccine Development
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–08348 Filed 4–24–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Description of Technology: It is
believed that immunization with an
effective immunogen based on the HIV–
1 envelope glycoprotein can elicit a
neutralizing antibody response, which
may be protective against HIV–1
infection. NIAID researchers have
discovered a new critical component of
the CD4-binding site in gp120, named
CD4–BS2, which is exclusively formed
in the trimeric envelope conformation.
It was further found that this newly
recognized region is critical for the
progression of the fusogenic mechanism
that leads to HIV–1 entry and infection
of the cells. This discovery may lead to
new methods of treatment, for treating
HIV–1, as well as to the production of
new vaccine immunogens.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
19073
development and evaluation under a
research collaboration.
Potential Commercial Applications:
New target for HIV therapeutic and
vaccine development.
Competitive Advantages: A new
molecular target discovered in this
invention may facilitate the
development of next-generation HIV
therapeutics and vaccines.
Development Stage: Proof-of-concept
studies demonstrate that CD4 binding to
CD4–BD2 is critical for triggering gp120
conformational changes that enable
coreceptor binding and HIV–1
infectivity. Animal studies are ongoing.
Inventors: Paolo Lusso, NIAID, NIH;
and Qingbo Liu, NIAID, NIH.
Publications: Liu, Qingbo, et al.
‘‘Quaternary contact in the initial
interaction of CD4 with the HIV–1
envelope trimer.’’ Nature Structural &
Molecular Biology (2017).
Intellectual Property: HHS Reference
No. E–230–2015/0—U.S. Patent
Application No. 62/292,750 filed 02/08/
2016; PCT Application No. PCT/
US2017/017038 filed 02/08/2017.
Licensing Contact: Chris Kornak, 240–
627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office (TTIPO) is
seeking parties interested in
collaborative research to further codevelop HIV–1 vaccines and/or
inhibitors that target the newly
recognized region. For collaboration
opportunities, please contact Chris
Kornak, 240–627–3705, chris.kornak@
nih.gov.
Dated: April 10, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–08351 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\25APN1.SGM
25APN1
]]>Agencies
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Pages 19071-19073]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08354]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee on the Validation of
Alternative Methods; Notice of Public Meeting; Request for Public Input
SUMMARY: The Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) will hold a public forum to share
information and facilitate direct communication of ideas and
suggestions from stakeholders. Interested persons may attend in person
or view the meeting remotely by webcast. Time will be set aside for
questions and public statements on the topics discussed. Registration
is requested for both public attendance and oral statements, and
required for remote access. Information about the meeting and
registration are available at https://ntp.niehs.nih.gov/go/iccvamforum-2017.
DATES:
Meeting: May 23, 2017, 9:00 a.m. to approximately 4:00 p.m. Eastern
Daylight Time (EDT).
Registration for Onsite Meeting: Deadline is May 12, 2017.
Registration for Webcast: Deadline is May 23, 2017.
Submission of Oral Public Statements: Deadline is May 12, 2017.
ADDRESSES:
Meeting Location: William H. Natcher Conference Center, National
Institutes of Health, Bethesda, MD 20892.
Meeting Web page: The preliminary agenda, registration, and other
meeting materials are at https://ntp.niehs.nih.gov/go/iccvamforum-2017.
FOR FURTHER INFORMATION CONTACT: Dr. Warren Casey, Director, National
[[Page 19072]]
Toxicology Program Interagency Center for the Evaluation of Alternative
Toxicological Methods (NICEATM); email: warren.casey@nih.gov;
telephone: (919) 316-4729.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM, a congressionally mandated committee, promotes
the development and validation of alternative testing strategies that
protect human health and the environment while replacing, reducing, or
refining animal use.
ICCVAM's goals include promotion of national and international
partnerships between governmental and nongovernmental groups, including
academia, industry, advocacy groups, and other key stakeholders. To
foster these partnerships ICCVAM initiated annual public forums in 2014
to share information and facilitate direct communication of ideas and
suggestions from stakeholders (79 FR 25136).
This year's meeting will be held on May 23, 2017, at the National
Institutes of Health (NIH) in Bethesda, MD. The meeting will include
presentations by NICEATM and ICCVAM members on current activities
related to the development and validation of alternative test methods
and approaches, including discussions of the proposed strategic roadmap
to establish new approaches for evaluating the safety of chemicals and
medical products in the United States. These new approaches are
anticipated to increase confidence in alternative methods and improve
their relevance to human health outcomes while maximizing efficiency
and maintaining a commitment to replace, reduce, and refine animal use.
Following each presentation, there will be an opportunity for
participants to ask questions of the ICCVAM members. Instructions for
submitting questions will be provided to remote participants prior to
the webcast. The agenda will also include time for participants to make
public oral statements relevant to the ICCVAM mission and current
activities.
Preliminary Agenda and Other Meeting Information: The preliminary
agenda, list of discussion topics, background materials, ICCVAM roster,
and public statements submitted prior to the meeting will be posted by
May 16 at https://ntp.niehs.nih.gov/go/iccvamforum-2017. Interested
individuals are encouraged to visit this Web page to stay abreast of
the most current meeting information.
Meeting and Registration: This meeting is open to the public with
time scheduled for questions and oral public statements following
presentations from ICCVAM and NICEATM. The public may attend the
meeting at NIH, where attendance is limited only by the space
available, or view remotely by webcast. Those planning to attend the
meeting in person are encouraged to register at https://ntp.niehs.nih.gov/go/iccvamforum-2017 by May 12, 2017, to facilitate
planning for appropriate meeting space. Those planning to view the
webcast must register at https://ntp.niehs.nih.gov/go/iccvamforum-2017;
registration will be available through May 23, 2017. The URL for the
webcast will be provided in the email confirming registration.
Visitor and security information for visitors to NIH is available
at https://www.nih.gov/about/visitor/index.htm. Individuals with
disabilities who need accommodation to participate in this event should
contact Dr. Elizabeth Maull at phone: (919) 316-4668 or email:
maull@niehs.nih.gov. TTY users should contact the Federal TTY Relay
Service at 800-877-8339. Requests should be made at least five business
days in advance of the event.
Request for Oral Public Statements: Each presentation will be
followed by an opportunity for participants to ask questions of the
presenter. Attendees need not register in advance for the opportunity
to ask questions or make comments specific to presentations.
Instructions for submitting questions or comments will be provided to
remote participants prior to the webcast.
In addition to time for questions or comments following each
scheduled presentation, time will be allotted during the meeting for
oral public statements with associated slides on topics relevant to
ICCVAM's mission and topics under discussion including the U.S.
strategic roadmap. The number and length of presentations may be
limited based on available time. Submitters will be identified by their
name and affiliation and/or sponsoring organization, if applicable.
Persons submitting public statements and/or associated slides should
include their name, affiliation (if any), mailing address, telephone,
email, and sponsoring organization (if any) with the document. National
Toxicology Program guidelines for public statements are at https://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_public_comments_508.pdf.
Persons wishing to present oral public statements are encouraged to
indicate on the registration form whether their comments will focus on
ICCVAM agency activities or the U.S. strategic roadmap. They should
also email their statement to ICCVAMquestions@niehs.nih.gov by May 12,
2017, to allow time for review by NICEATM and ICCVAM and posting to the
meeting page prior to the forum. Written statements may supplement and
expand the oral presentation. Public statements will be distributed to
NICEATM and ICCVAM members before the meeting.
Registration for oral public statements will be available onsite,
although onsite registration and time allotted for these statements may
be limited based on the number of individuals who register to make
statements and available time. If registering onsite and reading from
written text, please bring 20 copies of the statement for distribution
and to supplement the record.
Persons wishing to present oral public statements are strongly
encouraged to present their comments in person to facilitate effective
interaction with ICCVAM members. However, there will also be the
opportunity to present public statements by teleconference line.
Persons who are unable to attend the meeting in person and wish to
present oral public statements should email
ICCVAMquestions@niehs.nih.gov by May 12, 2017 to arrange to present
statements via teleconference line.
Responses to this notice are voluntary. No proprietary, classified,
confidential, or sensitive information should be included in statements
submitted in response to this notice or presented during the meeting.
This request for input is for planning purposes only and is not a
solicitation for applications or an obligation on the part of the U.S.
Government to provide support for any ideas identified in response to
the request. Please note that the U.S. Government will not pay for the
preparation of any information submitted or for its use of that
information.
Background Information on ICCVAM and NICEATM: ICCVAM is an
interagency committee composed of representatives from 16 federal
regulatory and research agencies that require, use, generate, or
disseminate toxicological and safety testing information. ICCVAM
conducts technical evaluations of new, revised, and alternative safety
testing methods and integrated testing strategies with regulatory
applicability. ICCVAM also promotes the scientific validation and
regulatory acceptance of testing methods that more accurately assess
the safety and hazards of chemicals and products and replace, reduce,
or refine animal use.
The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes
ICCVAM as a permanent interagency committee of the NIEHS and provides
[[Page 19073]]
the authority for ICCVAM involvement in activities relevant to the
development of alternative test methods. ICCVAM acts to ensure that new
and revised test methods are validated to meet the needs of federal
agencies, increase the efficiency and effectiveness of federal agency
test method review, and optimize utilization of scientific expertise
outside the federal Government. Additional information about ICCVAM can
be found at https://ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM, provides scientific and operational
support for ICCVAM-related activities, and conducts and publishes
analyses and evaluations of data from new, revised, and alternative
testing approaches. NICEATM and ICCVAM work collaboratively to evaluate
new and improved testing approaches applicable to the needs of U.S.
federal agencies. NICEATM and ICCVAM welcome the public nomination of
new, revised, and alternative testing approaches for validation studies
and technical evaluations. Additional information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/niceatm.
Dated: April 13, 2017.
John R. Bucher,
Associate Director, National Toxicology Program.
[FR Doc. 2017-08354 Filed 4-24-17; 8:45 am]
BILLING CODE 4140-01-P
